Aclaris Therapeutics Inc (NAS:ACRS)

$ 3.96 -0.11 (-2.7%) Market Cap: 282.87 Mil Enterprise Value: 172.04 Mil PE Ratio: 0 PB Ratio: 2.18 GF Score: 72/100

Q1 2024 Aclaris Therapeutics Inc Earnings Call Transcript
May 07, 2024

$1.34 (+2.29%)

Earnings
Aclaris Therapeutics Inc to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Call Transcript
Nov 13, 2023
Aclaris Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Aclaris Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Q1 2023 Aclaris Therapeutics Inc Earnings Call Transcript
May 08, 2023

$8.4 (-6.46%)

Earnings
Aclaris Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) Transcript
Mar 30, 2023
Aclaris Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Aclaris Therapeutics Inc R&D Day (Virtual) Transcript
Dec 07, 2021
Aclaris Therapeutics Inc ATI-1777 Clinical Data Call Transcript
Jun 08, 2021
Aclaris Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 03, 2021
Aclaris Therapeutics, Inc. - Special Call Transcript
Jan 19, 2021
Aclaris Therapeutics, Inc. - Special Call Transcript
Jun 17, 2020
Aclaris Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 04, 2020
Q4 2019 Aclaris Therapeutics Inc Earnings Call Transcript
Feb 25, 2020

$1.37 (-4.20%)

Earnings
Q3 2019 Aclaris Therapeutics Inc Earnings Call Transcript
Nov 07, 2019

$1.69 (+4.32%)

Earnings
Aclaris Therapeutics, Inc. - Special Call Transcript
Oct 24, 2019
Aclaris Therapeutics, Inc. - Special Call Transcript
Sep 27, 2019
Q2 2019 Aclaris Therapeutics Inc Earnings Call Transcript
Aug 08, 2019

$0.99 (-2.94%)

Earnings
Aclaris Therapeutics, Inc. - Special Call Transcript
Jul 30, 2019
Aclaris Therapeutics, Inc. - Special Call Transcript
Jun 26, 2019
Aclaris Therapeutics Presents 6-Month Results From Androgenetic Alopecia Study Transcript
Jun 17, 2019
Q1 2019 Aclaris Therapeutics Inc Earnings Call Transcript
May 08, 2019

$6.57 (-1.65%)

Earnings
Q4 2018 Aclaris Therapeutics Inc Earnings Call Transcript
Mar 18, 2019

Earnings

Aclaris Therapeutics, Inc. - Special Call Transcript

Oct 24, 2019 / 08:30PM GMT

Release Date Price: $1.68 (+1.82%)

Transcript 10-Q8-K

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Aclaris Therapeutics pivotal Phase III trial for the treatment of common warts conference call. (Operator Instructions) Please be advised, today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Kamil Ali-Jackson, Chief Legal Officer. Thank you. Please go ahead.

Kamil Ali;Jackson

Aclaris Therapeutics, Inc. - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary

Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued its press release announcing results from its Phase III clinical trial for the treatment of common warts, THWART-1. For those of you who have not yet seen it, you will find the release posted in the Investors section of our website at www.aclaristx.com.

Joining me today for the call are Dr. Neal Walker, President and Chief Executive

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.